OrganoClick

• It was resolved to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet.
• It was resolved that the accumulated result was brought forward and balanced in the new accounts according with the proposal of the Board.
• It was resolved to approve discharge from personal liability for the members of the Board of Directors and the CEO for their administration.
• It was resolved that the Board of Directors will have four ordinary board members.
• It was resolved in accordance with the nomination committee's proposal to pay a fixed fee of SEK 400.000 to the Chairman of the Board and a fixed fee of SEK 150.000 to the other ordinary members of the Board, in total a fee of SEK 850,000 to the Board, and that the Auditors’ fee's will be paid in accordance with current approved invoicing.
• It was resolved in accordance with the nomination committee’s proposal to re-elect Håkan Gustavson, Charlotte Karlberg, Chatarina Schneider and Johan Magnusson as board members. In accordance with the nomination committee’s proposal, Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board. 
• It was resolved in accordance with the nomination committee’s proposal to re-elect the registered accounting firm BDO Mälardalen AB, with authorized public accountant Emilie Sleth as auditor in charge for a period of one year until the end of the next Annual General Meeting.
• It was resolved to adopt the nomination procedure and election of nomination committee according to the proposal in the notice to the annual general meeting.
• It was resolved to adopt the boards proposal to authorise the Board of Directors during the period until the next annual general meeting, on one or more occasions, to resolve on a new issue of shares, stock options, or convertible bonds with or without deviation from the shareholders’ preferential rights to be paid in cash, in kind or by right of set-off. The issue may result in a total increase in the share capital by a maximum of 10% or SEK 98,118 (corresponding to 9,811,797 shares).
• It was resolved to adopt the nomination committee’s proposal that the payment of remuneration to the Board of Directors can be in the form of shares in the company or in cash
• It was resolved in accordance with the proposal from the Board to introduce a warrant-based incentive program through an issue of of 981,176 warrants of series 2025/2029:1 and to approve transfer of the warrants to senior executives in the Company (“Warrant Program 2025/2029:1”) in accordance with the proposal from the Board.

The CEO thereafter held a presentation were the previous years activities and the result of 2024 were presented including an outlook for 2025 (attached herein in Swedish). The presentation is also published on the company's webpage.

OrganoClick AB (publ)

The Board of Directors